Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Blacklock
J B
JB
M. D. Anderson Hospital, University of Texas System Cancer Center, Houston.
Grimm
E A
EA
D001932:Brain Neoplasms / Q000628:therapy*; D005910:Glioma / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*
D007376:Interleukin-2